| abstract |
The present invention relates to antibodies and molecules derived therefrom that bind the novel PSCA protein, and variants thereof, in which PSCA has tissue-specific expression in normal adult tissue, and is expressed aberrantly in the cancers listed in Table 1 Consequently, PSCA provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The PSCA gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune reaction; antibodies or T cells reactive with PSCA can be used in active or passive immunization. |